SCYNEXIS, Inc. (SCYX)
SCYX Stock Price Chart
Explore SCYNEXIS, Inc. interactive price chart. Choose custom timeframes to analyze SCYX price movements and trends.
SCYX Company Profile
Discover essential business fundamentals and corporate details for SCYNEXIS, Inc. (SCYX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2 May 2014
Employees
28.00
Website
https://www.scynexis.comCEO
David Gonzalez Angulo
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
SCYX Financial Timeline
Browse a chronological timeline of SCYNEXIS, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.21.
Earnings released on 13 Aug 2025
EPS came in at -$0.14 surpassing the estimated -$0.23 by +39.13%, while revenue for the quarter reached $1.36M , beating expectations by +785.71%.
Earnings released on 15 May 2025
EPS came in at -$0.17 surpassing the estimated -$0.23 by +26.09%, while revenue for the quarter reached $257.00K , beating expectations by +87.59%.
Earnings released on 12 Mar 2025
EPS came in at -$0.09 surpassing the estimated -$0.22 by +59.09%, while revenue for the quarter reached $977.00K , missing expectations by -90.41%.
Earnings released on 6 Nov 2024
EPS came in at -$0.06 surpassing the estimated -$0.20 by +70.00%, while revenue for the quarter reached $660.00K , missing expectations by -92.85%.
Earnings released on 8 Aug 2024
EPS came in at -$0.30 falling short of the estimated -$0.19 by -57.89%, while revenue for the quarter reached $736.00K , missing expectations by -93.98%.
Earnings released on 8 May 2024
EPS came in at -$0.15 surpassing the estimated -$0.18 by +16.67%, while revenue for the quarter reached $1.37M , missing expectations by -74.34%.
Earnings released on 28 Mar 2024
EPS came in at -$0.39 falling short of the estimated $0.31 by -225.81%, while revenue for the quarter reached $5.80M , beating expectations by +323.14%.
Earnings released on 13 Nov 2023
EPS came in at -$0.04 falling short of the estimated $0.29 by -113.79%, while revenue for the quarter reached $1.76M , beating expectations by +28.54%.
Earnings released on 14 Aug 2023
EPS came in at $2.46 surpassing the estimated $1.55 by +58.71%, while revenue for the quarter reached $131.45M , beating expectations by +37.72%.
Earnings released on 11 May 2023
EPS came in at -$0.25 surpassing the estimated -$0.28 by +10.71%, while revenue for the quarter reached $1.13M , missing expectations by -98.75%.
Earnings released on 31 Mar 2023
EPS came in at -$0.29 surpassing the estimated -$0.50 by +42.00%, while revenue for the quarter reached $1.52M , missing expectations by -2.93%.
Earnings released on 9 Nov 2022
EPS came in at -$0.62 falling short of the estimated -$0.51 by -21.57%, while revenue for the quarter reached $1.56M , missing expectations by -26.19%.
Earnings released on 15 Aug 2022
EPS came in at -$0.53 surpassing the estimated -$0.57 by +7.02%, while revenue for the quarter reached $1.32M , missing expectations by -21.17%.
Earnings released on 12 May 2022
EPS came in at -$0.51 surpassing the estimated -$0.74 by +31.08%, while revenue for the quarter reached $687.00K , missing expectations by -36.97%.
Earnings released on 29 Mar 2022
EPS came in at -$1.05 falling short of the estimated -$0.71 by -47.89%, while revenue for the quarter reached $597.00K , missing expectations by -52.59%.
Earnings released on 10 Nov 2021
EPS came in at -$0.06 surpassing the estimated -$0.79 by +92.41%, while revenue for the quarter reached $516.00K , missing expectations by -42.25%.
Earnings released on 16 Aug 2021
EPS came in at -$0.22 surpassing the estimated -$0.58 by +62.07%.
Earnings released on 17 May 2021
EPS came in at -$0.23 surpassing the estimated -$0.68 by +66.18%, while revenue for the quarter reached $12.05M , missing expectations by -35.97%.
Earnings released on 29 Mar 2021
EPS came in at -$1.47 falling short of the estimated -$0.78 by -88.46%.
Earnings released on 6 Nov 2020
EPS came in at -$0.28 surpassing the estimated -$1.07 by +73.83%.
SCYX Stock Performance
Access detailed SCYX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.